<?xml version="1.0" encoding="UTF-8"?>
<p id="Par38">Ipilimumab is a fully human monoclonal immunoglobulin (Ig) G1k specific for human CTLA-4 manufactured by Bristol Myers Squibb (BMS). Nivolumab is a human monoclonal antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) manufactured by BMS that inhibits the PD-1 receptor on cell surface. The clinical safety profile of nivolumab and ipilimumab as a combination therapy has emerged from a number of clinical studies in a number of tumour types [
 <xref ref-type="bibr" rid="CR17">17</xref>â€“
 <xref ref-type="bibr" rid="CR22">22</xref>].
</p>
